

Pear's schizophrenia app reaches the market - temporarily



[Elizabeth Cairns](#)

Pear Therapeutics has launched its fourth product, a prescription app for patients with schizophrenia, after the FDA loosened the rules governing digital health products as a response to the Covid-19 pandemic. Pear-004 has not been approved in the US or even studied in a pivotal trial, but the FDA's [recent enforcement policy for psychiatric digital health devices](#) means that this is not necessary. The policy aims to boost app use to reduce contact between patients and healthcare providers, but will remain in effect only for the duration of the public health emergency related to Covid-19; when that ends Pear will have to obtain formal approval, as it did with its three other marketed apps. Pear-004 provides neurobehavioral interventions such as social skills training, cognitive behavioural therapy for psychosis, and illness self-management training, and was developed in collaboration with Novartis under a deal that also covers a multiple sclerosis app. Novartis, however, does not appear to be involved in Pear-004's release.

Selected candidates in Pear's pipeline

Product	Indication	Status	Partner
Reset	Substance use disorder	Marketed	None; formerly Sandoz
Reset-O	Opioid use disorder	Marketed	None; formerly Sandoz
Somryst	Insomnia/depression	Marketed	None
Pear-004	Schizophrenia	Marketed (temporarily)	Novartis
Pear-007	Pain	Proof of concept	None
Pear-006	Multiple sclerosis	Discovery	Novartis
Unnamed	GI disorders	Discovery	Ironwood Pharmaceuticals

Source: company website.